- Home
- GLPG vs FINV Comparison
GLPG vs FINV Comparison
Compare GLPG & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- FINV
- Stock Information
- Founded
- GLPG 1999
- FINV 2007
- Country
- GLPG Belgium
- FINV China
- Employees
- GLPG N/A
- FINV N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- FINV Finance: Consumer Services
- Sector
- GLPG Health Care
- FINV Finance
- Exchange
- GLPG Nasdaq
- FINV Nasdaq
- Market Cap
- GLPG 2.1B
- FINV 2.0B
- IPO Year
- GLPG 2005
- FINV N/A
- Fundamental
- Price
- GLPG $32.02
- FINV $7.48
- Analyst Decision
- GLPG Sell
- FINV Strong Buy
- Analyst Count
- GLPG 4
- FINV 2
- Target Price
- GLPG $25.33
- FINV $11.55
- AVG Volume (30 Days)
- GLPG 198.2K
- FINV 2.4M
- Earning Date
- GLPG 10-29-2025
- FINV 08-20-2025
- Dividend Yield
- GLPG N/A
- FINV 3.79%
- EPS Growth
- GLPG N/A
- FINV 32.63
- EPS
- GLPG N/A
- FINV 1.49
- Revenue
- GLPG $323,674,692.00
- FINV $1,927,901,951.00
- Revenue This Year
- GLPG N/A
- FINV $13.45
- Revenue Next Year
- GLPG N/A
- FINV $9.59
- P/E Ratio
- GLPG N/A
- FINV $5.02
- Revenue Growth
- GLPG 5.43
- FINV 7.84
- 52 Week Low
- GLPG $22.36
- FINV $5.19
- 52 Week High
- GLPG $33.86
- FINV $11.08
- Technical
- Relative Strength Index (RSI)
- GLPG 49.28
- FINV 32.09
- Support Level
- GLPG $30.88
- FINV $7.74
- Resistance Level
- GLPG $33.63
- FINV $8.03
- Average True Range (ATR)
- GLPG 0.69
- FINV 0.28
- MACD
- GLPG -0.02
- FINV -0.08
- Stochastic Oscillator
- GLPG 41.45
- FINV 0.44
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.